These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 9425801)

  • 1. Cancer vaccines. Part 2.
    Hallin PA; Adams VR
    J Am Pharm Assoc (Wash); 1997; NS37(6):706-9. PubMed ID: 9425801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer vaccines: a critical review on clinical impact.
    Bitton RJ
    Curr Opin Mol Ther; 2004 Feb; 6(1):17-26. PubMed ID: 15011777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
    Gulley JL; Arlen PM; Bastian A; Morin S; Marte J; Beetham P; Tsang KY; Yokokawa J; Hodge JW; Ménard C; Camphausen K; Coleman CN; Sullivan F; Steinberg SM; Schlom J; Dahut W
    Clin Cancer Res; 2005 May; 11(9):3353-62. PubMed ID: 15867235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New advances in clinical trials of cancer vaccines].
    Peng F; Wei YQ
    Ai Zheng; 2006 Aug; 25(8):1059-62. PubMed ID: 16965694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
    Morton DL
    Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Vaccine therapy of prostate cancer].
    Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D
    Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
    Hsueh EC; Morton DL
    Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
    Berinstein NL
    Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
    Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for prostate cancer - recent progress in clinical trials.
    Kipp RT; McNeel DG
    Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melacine: an allogeneic melanoma tumor cell lysate vaccine.
    Sosman JA; Sondak VK
    Expert Rev Vaccines; 2003 Jun; 2(3):353-68. PubMed ID: 12903801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2.
    Shimizu K; Fields RC; Redman BG; Giedlin M; Mulé JJ
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S67-75. PubMed ID: 10685663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospects for vaccine therapy for pancreatic cancer.
    Gaudernack G
    Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):299-314. PubMed ID: 16549329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man--clinical trials at Memorial Sloan-Kettering Cancer Center.
    Slovin SF; Scher HI
    Semin Oncol; 1999 Aug; 26(4):448-54. PubMed ID: 10482187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell vaccines in melanoma: from promise to proof?
    Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
    Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor vaccination: where we stand.
    Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
    Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine therapy for prostate cancer.
    Sonpavde G; Spencer DM; Slawin KM
    Urol Oncol; 2007; 25(6):451-9. PubMed ID: 18047951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.